Alterity Therapeutics (ATHE) Long-Term Investments (2017)
Alterity Therapeutics (ATHE) posted Long-Term Investments of $120498.3 for Q4 2017, up 6.94% on a QoQ basis from $112681.5 in Q2 2017.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Long-Term Investments (2017) Analysis & Trends
Alterity Therapeutics has reported Long-Term Investments for 1 years, with the latest figure at $120498.3 in Q4 2017.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $120498.3 in Q4 2017; TTM through Dec 2017 was $120498.3, a N/A change from a year earlier, with the FY2017 full-year figure at $113109.4, changed N/A from the prior year.
- Long-Term Investments was $120498.3 for Q4 2017 at Alterity Therapeutics, up from $112681.5 in the prior quarter.
- The five-year high for Long-Term Investments was $120498.3 in Q4 2017, with the low at $112681.5 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - | - |